Skip to content

EBITDA at other companies

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$28.23M+21.9%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$86.83M+11.0%
Stryker logo
StrykerSYK
Cardinal Health logo
Cardinal HealthCAH
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Calculated from Avanos Medical’s reported figures.

$8.9Mebit+
$10.2MDepreciation Depletion & Amortization
=$19.1M

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's EBITDA?
Avanos Medical (AVNS) reported EBITDA of $19.1M in Q1 2026.
How has Avanos Medical's EBITDA changed year-over-year?
Avanos Medical's EBITDA decreased by 4.0% year-over-year, from $19.9M to $19.1M.
What is the long-term trend for Avanos Medical's EBITDA?
Over 4 years (2021 to 2025), Avanos Medical's EBITDA has grown at a 181.7% compound annual growth rate (CAGR), from -$400K to -$25.2M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.